Ganymede

Ganymede Bio is a cloud infrastructure provider founded in 2022 and headquartered in Palo Alto, California. The company's core offering is a data platform powered by its proprietary Lab-as-Code technology, which enables scientists and bioinformaticians to integrate lab instruments, applications, and data pipelines in a single cloud data layer. Ganymede's platform allows users to write real-time integrations and scientific analyses in a low-code cloud integrated development environment (IDE), connecting directly to lab instruments and scientific software. This approach aims to streamline data management and automation in biotech and pharmaceutical laboratories, addressing the industry's challenges with fragmented and complex data sources.

The company's solution automatically integrates data from various sources into a structured, cloud-based database, storing it indefinitely to aid compliance with regulatory requirements. Ganymede's platform is designed to be flexible and self-service, allowing clients to write their own integrations or adapt existing ones with minimal code changes. The technology supports integration with various tools such as electronic lab notebooks (ELNs), laboratory information management systems (LIMS), quality management systems (QMS), and manufacturing execution systems (MES).

Ganymede's approach focuses on making scientific data FAIR (Findable, Accessible, Interoperable, and Reusable), which is crucial for ensuring data integrity and empowering scientists to focus more on actual science rather than data management tasks. As of December 2022, the company had exceeded USD 1 million in revenue commitments, with a client base ranging from early-stage biotechs to large, established biopharmaceutical companies.

Key customers and partnerships

Ganymede Bio has established partnerships with several companies in the biotech and pharmaceutical industries. One of its earliest partners is Apprentice, whose CEO Angelo Stracquatanio praised Ganymede's speed and flexibility in integrating instruments through Lab-as-Code. In September 2023, Ganymede announced a partnership with Kytopen, a biotechnology company specializing in non-viral transfection tools for genome engineering. This collaboration aims to bring cloud-native, structured data capabilities to Kytopen's Flowfect platforms, including the Flowfect Discover (an automated high-throughput screening device) and the Flowfect Tx (a manufacturing-scale gene delivery device). The partnership is expected to enhance analytical capabilities and streamline data management for Kytopen's customers in the cell and gene therapy field.